Drugs / 131I-IPA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05450744 | Apr 2023 → Jun 2026 overdue | glioblastoma | Telix Pharmaceuticals (Innovations) Pty Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 131I-IPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05450744 ↗ |
| Route | Intravenous | “administrated intravenously via infusion” NCT05450744 ↗ |